Background: In breast tissue, pre-malignant lesions are classified as BIRADS 3. The treatment of this heterogeneous group varies with expertise and tools available.
Materials and methods: With the example of two case reports, the literature is reviewed on current treatment options for BIRADS 3 breast lesions.
Results: About 7% of all B-type breast biopsies fall into the B3 category. Approximately 35% of these B3 lesions are due to FEA, 20% to PLs and another 20% to ADH. Due to improvement in diagnostics, the incidence is increasing, while their value as a predictive factor for malignancy has steadily been fallen.
Conclusion: Depending on the histology of the needle biopsy, a complete resection with vacuum-assisted biopsy may be a treatment alternative to open biopsy.